After AWMSG endorsement, AWTTC sends the recommendation to Welsh Government for ratification.
Welsh Government decides if a medicine should be funded in NHS Wales. If Welsh Government ratifies (approves) AWMSG's positive (including positive with restrictions) recommendation and the medicine is launched in the UK and any commercial arrangements are in place, the medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Health Boards and NHS Wales Joint Commissioning Committee are expected to fund the medicine according to the recommendation. Funding variations may be agreed by exception and in specified circumstances (details to follow).
AWMSG recommendations for licensed medicines will usually be superseded by any NICE HTA guidance published for the same licensed medicine and indication(s). If NICE subsequently terminates an HTA, then the AWMSG advice will continue to stand.
After Welsh Government has ratified recommendations for off-label medicines, the decision is disseminated to appropriate organisations and individuals in NHS Wales for implementation. Health Boards and the NHS Wales Joint Commissioning Committee are expected to fund the medicine according to the recommendation.